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Background:  The  currently  recommended  single  dose of the  23-valent  pneumococcal  free  polysaccharide
vaccine  (PPSV23)  for  adults  65 years  of age  and  older  does  not  provide  extended  protection  into  older  age.
This reﬂects  a signiﬁcant  unmet  medical  need  for alternative  strategies  to protect  older  adults  against
pneumococcal  infection,  which  may  be  met  by  the  13-valent  polysaccharide  conjugate  vaccine  (PCV13).
Methods:  We  performed  a  randomized,  modiﬁed  double-blind  trial  in  936  adults  aged  70 years  and  older
who  had  previously  received  PPSV23  at least  5 years  before  study  entry  and  were  now  vaccinated  with
PCV13  or  PPSV23.  At  1 year  after  enrollment,  all  subjects  received  a  follow-on  dose  of PCV13.  Anti-
pneumococcal  opsonophagocytic  activity  (OPA)  titers  were  measured  before  and at 1  month  after  each
vaccination.
Results: Following  the  enrollment  vaccination,  OPA  titers  were  signiﬁcantly  greater  in the  PCV13  group
compared  to the  PPSV23  group  for 10 of  the 12  serotypes  common  to  both  vaccines  and  to  serotype  6A
which  is  unique  to  PCV13.  Responses  were  noninferior  for the  other  2 common  serotypes.  Responses  to
re  ge
d  70  
c  thaPCV13  given  at 1  year  we
Conclusion:  In adults  age
cantly  more  immunogeni
responses  after  a follow-on  do
PCV13,  diminishes  the  respons
© 201
Abbreviations: ACIP, United States Advisory Committee on Immunization Prac-
ices; AE, adverse event; CI, conﬁdence interval; CRM197, cross-reactive material
97; GMR, geometric mean ratio; GMT, geometric mean titer; ITP, idiopathic
hrombocytopenic purpura; OPA, opsonophagocytic activity; PCV, pneumococ-
al  polysaccharide conjugate vaccine; PCV13, 13-valent pneumococcal conjugate
accine; PPSV23, 23-valent polysaccharide vaccine; RCDC, reverse cumulative dis-
ribution curve; SAE, serious adverse event.
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Open access under CC BY-NC-ND nerally  lower  in  the  group that  received  PPSV23  at  enrollment.
years  and  older  previously  vaccinated  with  PPSV23,  PCV13  was  signiﬁ-
n  PPSV23  for most  of the common  serotypes  and  for  serotype  6A.  The  OPA
se  of  PCV13  one  year  later  indicate  that  a prior dose  of  PPSV23,  but  not
e  to  the  subsequent  administration  of  PCV13.
3 The Authors. Published by Elsevier Ltd. 
1. Introduction
A single dose of the 23-valent pneumococcal polysaccharide
vaccine (PPSV23) is currently recommended for all adults 65 years
of age and older. In the United States the majority of adults in
this age group have received this vaccine [1]. As with other free
polysaccharide vaccines, the duration of efﬁcacy of PPSV23 is
limited, approximately 3–5 years, indicating a need for periodic
revaccination [2]. However, the United States Advisory Committee
on Immunization Practices (ACIP) “does not recommend routine
revaccinations with PPSV23 because of insufﬁcient data regarding
clinical beneﬁt, particularly the degree and duration of protection,
Open access under CC BY-NC-ND license.and safety” [1,3]. Receipt of a ﬁrst dose of PPSV23 has been shown
to blunt the immune response to subsequent vaccinations, and thus
administration of additional doses of PPSV23 may  not extend the
duration of protection [1,4–7].
license. 
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Given that the risk of pneumococcal infection continues to rise
ith advancing age, there exists a need for a pneumococcal vac-
ination strategy that will provide extended protection over the
ecades following the 65th birthday.
We conducted a randomized clinical trial to evaluate safety and
mmunogenicity of PCV13 compared to PPSV23 in adults aged 70
ears and older who had been previously vaccinated with PPSV23
t least 5 years before enrollment. The study also assessed adminis-
ration of PCV13 in both groups 1 year after initial study vaccination.
. Methods
.1. Study design and population
This was a randomized, modiﬁed double-blind, multicenter (46
enters in USA, 7 centers in Sweden), phase 3 trial of adults 70
ears and older who had received 1 dose of PPSV23 at least 5 years
efore enrollment. This study was undertaken in accordance with
he Declaration of Helsinki and Good Clinical Practice [8,9]. After
btaining informed consent, subjects with documented vaccination
ith 1 dose of PPSV23 were randomized with equal probability to
eceive 13-valent pneumococcal vaccine (PCV13) or PPSV23 using a
andomized block design at the enrollment visit (year 0); all partic-
pants received open label PCV13 1 year later (year 1) (Fig. 1). In the
odiﬁed double-blind design PCV13 and PPSV23 were dispensed
nd administered by unblinded study staff members who  were not
nvolved in subsequent participant assessments. All other study
taff members and the participants were blinded to the vaccine
dministered at enrollment. PCV13 given at year 1 was  open-label.
The study allowed enrollment of subjects with pre-existing
hronic underlying conditions (e.g., cardiovascular, pulmonary,
iver diseases including alcoholic liver disease and alcoholism, renal
nd urinary disorders or diabetes mellitus). Disease had t o be
table, deﬁned as not requiring signiﬁcant change in therapy or
ospitalization for worsening disease 12 weeks prior to vaccina-
ion. Underlying diseases were assessed by obtaining the subject’s
edical history, including prior vaccinations over the previous 5
ears, reviewing medical records and performing a physical exam-
nation at study enrollment. In order to minimize confounding
mmunological variables in the study, subjects were excluded if
hey had serious chronic disorders including metastatic malig-
ancy, severe chronic obstructive pulmonary disease requiring
upplemental oxygen, end stage renal disease with or without dial-
sis, clinically unstable cardiac disease, impaired immune function
e.g. HIV infection), or had previously received more than 1 PPSV23
ose or any prior pneumococcal conjugate vaccine (PCV). Other rea-
ons for exclusion included receipt of a diphtheria toxin-containing
accine in the previous 6 months or current antibiotic therapy.
The study included clinic visits for vaccination and 1 month
29–43 days) after each vaccination. The study also included
 telephone call to inquire about any serious adverse events
SAEs), hospitalizations, newly diagnosed chronic medical condi-
ions (including autoimmune or neuroinﬂammatory diseases) and
mergency room visits that meet the criteria of an SAE since the
ast visit. Blood samples were obtained immediately before and
pproximately 1 month after each vaccination.
.2. Vaccines and administration
PCV13 (Prevenar13/Prevnar 13®, Wyeth Vaccines; Lot Num-
er 7-5095-005A) contains polysaccharides of pneumococcal
erotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F indi-
idually conjugated to a nontoxic mutant form of diphtheria toxin
ross-reactive material 197 (CRM197) protein, 0.85% sodium chlo-
ide, 0.02% polysorbate 80, and 0.125 mg  aluminum as aluminum1 (2013) 3585– 3593
phosphate, per 0.5 mL  dose. The vaccine is formulated to contain
2.2 g of each saccharide, except for 4.4 g of 6B, per 0.5 mL  dose,
is supplied in single-dose syringes without preservatives and stored
at 2–8 ◦C.
PPSV23 (Pneumovax 23®, Merck & Co., Inc.; Lot Numbers 0993U,
0486U, A0984-2) consists of puriﬁed capsular polysaccharides from
12 of the serotypes included in PCV13 (all except 6A), as well as 11
additional serotypes (2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and
33F). The vaccine is formulated to contain 25 g of each of the 23
puriﬁed polysaccharide serotypes per 0.5 mL  dose of vaccine and
contains phenol as a preservative and stored at 2–8 ◦C.
Vaccines were administered by intramuscular injection in the
deltoid using 25 G 1 inch needles.
2.3. Study objectives
The primary study objectives for the initial (year 0) vaccina-
tions were demonstration that PCV13 is at least as immunogenic
as PPSV23 for the 12 common serotypes, as measured by
opsonophagocytic activity (OPA) titers 1 month after initial study
vaccination, and demonstration that the proportion of subjects
with a 4-fold increase in OPA titer to serotype 6A (only in PCV13) is
signiﬁcantly greater after PCV13 compared to PPSV23. A secondary
objective was demonstration that PCV13 is statistically signiﬁ-
cantly more immunogenic than PPSV23 for at least some of the
12 common serotypes and serotype 6A.
Secondary objectives for the follow-on (year 1) administration
of PCV13 were (1) demonstration that OPA responses to a second
dose of PCV13 are noninferior to the initial dose of PCV13 or to the
initial dose of PPSV23 for the 12 common serotypes, (2) demon-
stration that the OPA response to serotype 6A after a second PCV13
dose is statistically signiﬁcantly greater than after the initial PPSV23
dose. See other immune response comparisons in Section 3.
2.4. Analysis populations
The evaluable immunogenicity populations for vaccinations 1
and 2 were the primary populations for immunogenicity analy-
ses and consisted of eligible subjects who had at least 1 valid and
determinate assay result, received the assigned vaccine and no pro-
hibited vaccines, and had no major protocol violation. The safety
population included all subjects who  received at least 1 dose of
study vaccine.
2.5. Immunogenicity assessments
The primary endpoint for the study was to evaluate anti-
pneumococcal responses for each of the 13 pneumococcal
serotypes contained in PCV13 by measuring speciﬁc functional
antibacterial OPA titers using validated OPA assays [10]. The OPA
testing was  performed by Pﬁzer’s Vaccine Research Clinical Testing
laboratory. All laboratory staff were blinded to the vaccine status.
OPA titers were deﬁned as the interpolated reciprocal serum dilu-
tion that resulted in complement-mediated killing of 50% of the
assay bacteria. The lowest titer that can be determined in the assay
(limit of detection [LOD]), regardless of serotype, is 1:8. However,
to quantify functional antibodies with appropriate precision and
accuracy, the lower limit of quantitation (LLOQ) was determined
for each serotype-speciﬁc OPA assay during assay validation. Titers
below the LLOQ were set to a value of 1:4 (half of the LOD).
2.6. Safety assessmentsParticipants recorded local reactions, systemic events, and oral
temperature in an electronic diary on the evening of vaccination
and for the next 13 days. Adverse events (AEs) were recorded
L.A. Jackson et al. / Vaccine 31 (2013) 3585– 3593 3587
Fig. 1. Study design and disposition of subjects.
3 ccine 31 (2013) 3585– 3593
f
o
f
t
2
2
o
P
[
(
d
p
0
m
2
(
c
t
e
g
2
S
l
2
d
1
t
c
b
i
l
(
p
2
h
N
2
e
i
[
3
3
s
w
ﬁ
i
w
u
v
ﬁ
o
e
Table 1
Baseline characteristics.
Characteristic PCV13
N = 463
PPSV23
N = 473
Female (%) 47.7 49.7
Race (%)
White 95.9 96.0
Black 2.6 2.1
Asian 0.6 1.7
Other 0.4 0
American Indian or Alaska Native 0.2 0.2
Native Hawaiian or Other Paciﬁc Islander 0.2 0
Hispanic or Latino 0.6 1.1
Any chronic underlying diseases (%) 36.9 48.4
Cardiovascular disease 18.4 21.8
Liver diseases 0.9 0.4
Pulmonary diseases 13.0 9.5
Diabetes mellitus 15.3 16.1
Renal and urinary disorders 5.2 3.6
Mean age (years (SD)) 76.7 (4.6) 76.7 (4.5)
Range (years) 70.1 (95.5) 70.0 (94.7)
70–74 years (%) 42.5 43.6
75–79 years (%) 33.7 33.4
≥80 years (%) 23.8 23.0
3.2.1. PCV13 compared to PPSV23 (year 0)
OPA GMTs elicited by PCV13 were noninferior to those
elicited by PPSV23 for all 12 common serotypes and statistically
Table 2
Comparison of pneumococcal OPA GMTs 1 month after PCV13 vs. PPSV23 given at
year 0.
Serotype PCV13 vs. PPSV23
PCV13
na = 400–426
PPSV23
na = 395–445
Vaccine comparison
GMTb GMTb GMT  ratioc (95% CId)
1 81 55 1.5 (1.17, 1.88)
3  55 49 1.1 (0.91, 1.35)
4  545 203 2.7 (1.93, 3.74)
5  72 36 2.0 (1.55, 2.63)
6B 1261 417 3.0 (2.21, 4.13)
7F 245 160 1.5 (1.07, 2.18)
9V 181 90 2.0 (1.36, 2.97)
14 280 285 1.0 (0.73, 1.33)
18C 907 481 1.9 (1.42, 2.50)
19A 354 200 1.8 (1.43, 2.20)
19F 333 214 1.6 (1.17, 2.06)
23F 158 43 3.7 (2.69, 5.09)
6A 903 94 9.6 (7.00, 13.26)
Serotypes in bold demonstrated a statistically signiﬁcantly greater OPA response in
PCV13 recipients compared with PPSV23 recipients.
a n = Number of subjects with a determinate OPA antibody titer to the given
serotype.
b GMTs were calculated using all evaluable subjects with available data for both
the  speciﬁed blood draw.
c588 L.A. Jackson et al. / Va
rom enrollment through the month 1 postvaccination visit, seri-
us adverse events (SAEs) from enrollment through the 6 month
ollow-up phone contact after each vaccination, and deaths through
he end of the study.
.7. Statistical analysis
.7.1. Sample size estimation
The sample size estimation was based on the OPA response to 7
f the 13 serotypes in PCV13 that were reported in a trial of 7-valent
CV (PCV7) in adults ≥70 years previously vaccinated with PPSV23
11]. The sample size of approximately 462 subjects per study group
924 total) was determined to provide at least 90% overall power to
eclare noninferiority of PCV13 versus PPSV23 for the 12 common
neumococcal antigens using a 2-fold noninferiority criterion of
.5, 2-sided type 1 error rate of 0.05, and a dropout rate of not
ore than 12%.
.7.2. Immunogenicity analyses
For the pairwise comparison of OPA geometric mean titers
GMTs) between vaccine groups and sequences, the 2-sided 95%
onﬁdence intervals (CIs) (based on the Student t distribution) for
he geometric mean ratio (GMR) (GMT group 1/GMT group 2) for
ach of the common serotypes was calculated. Noninferiority of
roup 1 relative to group 2 was declared if the lower limit of the
-sided 95% CI for the GMR  was greater than 0.5 (2-fold criterion).
tatistically signiﬁcantly higher response was declared if the lower
imit of the 95% CI for the GMR  was greater than 1.0 (greater than
.0 for serotype 6A). Statistically signiﬁcantly lower responses were
eclared if the upper limit of the 95% CI for the GMR  was  less than
.0.
Difference in the proportion of subjects achieving a 4-fold rise in
he OPA titer for serotype 6A at 1 month after initial vaccination was
omputed between PCV13 and PPSV23 with corresponding 95% CIs
ased on Chan and Zhang methodology [12]. Statistically signif-
cantly higher response for the PCV13 group was declared if the
ower limit of the 2-sided 95% CI for the difference in proportions
PCV13–PPSV23) was greater than zero.
For the within group comparison (PCV13/PCV13), analyses were
erformed using data only from those subjects who  had received
 administrations of PCV13 given a year apart (PCV13/PCV13) and
ad serotype speciﬁc OPA data after both vaccinations.
All analyses were performed using the SAS software package.
o imputations were done for missing data.
.7.3. Safety analyses
Comparisons of the incidence of local reactions and systemic
vents between vaccine groups were performed with correspond-
ng 95% CIs and p-values based on Chan and Zhang methodology
12].
. Results
.1. Baseline characteristics and disposition of subjects
A total of 936 subjects were vaccinated and included in the
afety population. Of these, 879 (431 with PCV13; 448 with PPSV23)
ere included in the evaluable immunogenicity population for the
rst vaccination (year 0). For year 1, a total of 795 subjects were
ncluded in the safety population and 745 (372 with PCV13; 373
ith PPSV23) were included in the evaluable immunogenicity pop-
lation (Fig. 1). Distribution of age, sex, race, and ethnicity at ﬁrst
accination were similar in both groups (Table 1). At the time of the
rst vaccination 36.9% and 48.4% of subjects who received PCV13
r PPSV23, respectively had 1 or more chronic underlying dis-
ases (cardiovascular diseases 18.4/21.8%, liver diseases 0.9/0.4%,Abbreviations: PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-
valent pneumococcal polysaccharide vaccine; SD, standard deviation.
pulmonary diseases 13.0/9.5%, diabetes mellitus 15.3/32.6%, renal
disorders, 5.2/3.6%). There was a higher proportion of subjects with
chronic underlying diseases in the PPSV23 group primarily due to
a higher rate of subjects with diabetes mellitus (Table 1).
3.2. Immune responsesRatio of GMTs (PCV13 to PPSV23) is calculated by back transforming the mean
difference between vaccine groups on the logarithmic scale.
d CIs for the ratio are back transformations of a conﬁdence interval based on the
Student t distribution for the mean difference of the logarithms of the measures
(PCV13–PPSV23).
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Table 3
Comparison of pneumococcal OPA GMTs 1 month after PCV13/PCV13 (year 1) vs. PCV13 or PPSV23 (year 0).
Serotype PCV13/PCV13 vs. PCV13 PCV13/PCV13 vs. PPSV23
PCV13/PCV13
na = 324–361
PCV13
na = 324–361
Vaccine comparison PCV13/PCV13
na = 347–370
PPSV23
na = 395–445
Vaccine comparison
GMTb GMTb GMT ratioc (95% CId)e GMTb GMTb GMT ratioc (95% CId)
1 76 79 1.0 (0.85, 1.10) 76 55 1.4 (1.10, 1.76)
3  55 55 1.0 (0.91, 1.11) 55 49 1.1 (0.91, 1.34)
4  487 614 0.8 (0.68, 0.92) 472 203 2.3 (1.66, 3.25)
5  57 69 0.8 (0.73, 0.94) 56 36 1.6 (1.21, 2.06)
6B  1590 1358 1.2 (1.02, 1.35) 1565 417 3.8 (2.78, 5.07)
7F  180 222 0.8 (0.65, 1.01) 185 160 1.2 (0.80, 1.67)
9V  166 187 0.9 (0.69, 1.15) 158 90 1.8 (1.18, 2.62)
14  241 265 0.9 (0.79, 1.05) 238 285 0.8 (0.62, 1.13)
18C  1003 918 1.1 (0.97, 1.23) 975 481 2.0 (1.53, 2.69)
19A  341 349 1.0 (0.89, 1.07) 339 200 1.7 (1.37, 2.10)
19F  322 329 1.0 (0.83, 1.15) 311 214 1.5 (1.09, 1.93)
23F  309 167 1.9 (1.60, 2.14) 310 43 7.3 (5.36, 9.82)
6A  1169 971 1.2 (1.03, 1.40) 1134 94 12.1 (8.92, 16.44)
Serotypes in bold demonstrated a statistically signiﬁcantly greater OPA response following the second administration of PCV13 compared to the initial PCV13 or initial
PPSV23 administration. Serotypes in italics demonstrated a statistically signiﬁcantly lower OPA response following the second administration of PCV13 compared to the
initial  PCV13 administration.
a n = Number of subjects with a determinate OPA antibody titer to the given serotype.
b GMTs were calculated using all evaluable subjects with available data for both the speciﬁed blood draws.
c Ratio of GMTs is calculated by back transforming the mean difference between vaccine groups/sequence on the logarithmic scale.
d CIs for the ratio are back transformations of a conﬁdence interval based on the Student t distribution for the mean difference of the logarithms of the measures.
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igniﬁcantly greater for 10 of the 12 common serotypes (Table 2)
nd serotype 6A.
For serotype 6A, the proportion of subjects achieving a 4-fold
ncrease in OPA titer was signiﬁcantly higher in the PCV13 group
71.1%) compared to the PPSV23 group (27.3%). The difference in
roportions was 43.8% (95% CI, 37.4% to 49.9%).
Reverse cumulative distribution curves (RCDC; Supp Fig. 1)
how that PCV13 responses were higher across the full range of
PA titers for the 10 serotypes for which PCV13 was  statistically
igniﬁcantly more immunogenic than PPSV23 and similar for the
ther 2 serotypes.
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.vaccine.
013.05.010.
.2.2. PCV13 following initial PCV13 (PCV13/PCV13) compared to
nitial PCV13
OPA GMTs following the second administration, were noninfe-
ior to responses after the initial PCV13 administration for all 13
erotypes, statistically signiﬁcantly greater for serotypes 6A, 6B,
nd 23F, and statistically signiﬁcantly lower for serotypes 4 and 5
Table 3). Nonetheless, the RCDCs show that responses increased
rom before to after the second administration. Following the sec-
nd administration, the elicited responses were generally similar
hroughout the population to those seen after the initial adminis-
ration (Supp Fig. 2).
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.vaccine.
013.05.010.
.2.3. PCV13/PCV13 compared to initial PPSV23
OPA GMTs following the second administration of PCV13 wereoninferior to those after the year 0 administration of PPSV23 for
ll 12 common serotypes with statistically signiﬁcantly greater
esponses for 9 of the 12 common serotypes and for serotype 6A
Table 3).r own  control across time and GMTs are derived for subjects with data at both time
3.2.4. PPSV23/PCV13 compared to initial PCV13
OPA GMTs following PCV13 administered after PPSV23 were
statistically signiﬁcantly lower for all 13 serotypes compared to
responses after initial administration of PCV13 (Table 4).
3.2.5. PCV13/PCV13 compared to PPSV23/PCV13
OPA GMTs following 2 administrations of PCV13 were statis-
tically greater for 12 of 13 serotypes compared to the responses
following PCV13 given after PPSV23 (Table 4).
Antibody levels decreased over time after the initial adminis-
tration of PCV13 or PPSV23, but remained higher for PCV13/PCV13
compared to PPSV23/PCV13 at all time points for most serotypes
(data not shown).
3.2.6. Subanalysis for age groups 70–74 years, 75–79 years and ≥
80 years of age
OPA GMTs of PCV13 and PPSV23 were compared descriptively
post hoc in subjects 70–74 years, 75–79 years and ≥80 years of age.
The responses of PCV13 were similar in age subgroups 70–74 and
75–79 years of age and were slightly lower in subjects ≥80 years of
age. PCV13 responses were greater than PPSV23 responses for the
majority of serotypes across all age groups (data not shown).
3.3. Safety
Following the initial study vaccination, a signiﬁcantly higher
proportion of subjects vaccinated with PPSV23 reported local reac-
tions compared to subjects vaccinated with PCV13 (Table 5). All
subjects received PCV13 as a second vaccination with no signiﬁ-
cant differences in local reactions between the 2 vaccine groups
and no increase in reactions compared to the initial dose of PCV13.
Following the initial study vaccination, frequency of fever was
low and similar between both groups. The percentages of subjects
reporting fatigue, rash, new and aggravated generalized muscle
pain and any systemic event were signiﬁcantly higher after PPSV23
(Table 5). After the second vaccination, a signiﬁcantly higher inci-
dence of vomiting was  observed after PPSV23/PCV13 relative to
PCV13/PCV13 with low frequencies in both groups (3.1% vs. 0.4%).
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Table 4
Comparison of pneumococcal OPA GMTs 1 month after PPSV23/PCV13 (year 1) vs. PCV13 (year 0) and PCV13/PCV13 (year 1) vs. PPSV23/PCV13 (year 1).
Serotype PPSV23/PCV13 vs. PCV13 PCV13/PCV13 vs. PPSV23/PCV13
PPSV23/PCV13
na = 338–367
PCV13
na = 400–426
Vaccine comparison PCV13/PCV13
na = 347–370
PPSV23/PCV13
na = 338–367
Vaccine comparison
GMTb GMTb GMT  ratioc (95% CId) GMTb GMTb GMT  ratioc (95% CId)
1 34 81 0.4 (0.33, 0.54) 76 34 2.2 (1.74, 2.82)
3  33 55 0.6 (0.49, 0.74) 55 33 1.7 (1.36, 2.03)
4  267 545 0.5 (0.36, 0.67) 472 267 1.8 (1.29, 2.42)
5  42 72 0.6 (0.44, 0.76) 56 42 1.4 (1.03, 1.79)
6B  721 1261 0.6 (0.42, 0.78) 1565 721 2.2 (1.61, 2.94)
7F  120 245 0.5 (0.34, 0.71) 185 120 1.5 (1.05, 2.24)
9V  72 181 0.4 (0.27, 0.59) 158 72 2.2 (1.47, 3.32)
14  194 280 0.7 (0.51, 0.95) 238 194 1.2 (0.89, 1.68)
18C  513 907 0.6 (0.43, 0.74) 975 513 1.9 (1.45, 2.49)
19A  248 354 0.7 (0.56, 0.86) 339 248 1.4 (1.11, 1.68)
19F  180 333 0.5 (0.40, 0.72) 311 180 1.7 (1.30, 2.30)
23F  87 158 0.6 (0.39, 0.78) 310 87 3.6 (2.57, 4.93)
6A  549 903 0.6 (0.44, 0.83) 1134 549 2.1 (1.54, 2.77)
Serotypes in italics demonstrated a statistically signiﬁcantly lower OPA response following PCV13 administered after PPSV23 compared to the initial PCV13 administration.
Serotypes in bold demonstrated a statistically signiﬁcantly greater OPA response following 2 administrations of PCV13 compared to PCV13 given after PPSV23.
a n = Number of subjects with a determinate OPA antibody titer to the given serotype.
b GMTs were calculated using all evaluable subjects with available data for both the speciﬁed blood draws.
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o other signiﬁcant differences were observed among systemic
vents and there was no increase in systemic events compared to
he initial dose of PCV13. There were no vaccine related SAEs at 1
onth and 6 months after the initial vaccination.
The only SAE considered by the investigator to be related to the
tudy vaccine was idiopathic thrombocytopenic purpura (ITP) of a
1-year-old male 132 days after the second vaccination in the group
hat received PPSV23/PCV13. The ITP resolved after treatment. Nine
9) subjects died during the study. Eight (8) of the subjects (4 in the
CV13 group and 4 in the PPSV23 group) died after vaccination
 (day 72 to day 309 after vaccination). One subject died on day
5 after vaccination 2. None of the events leading to death were
onsidered related to study vaccine.
. Discussion
The risk of pneumococcal infections continues to rise in the
ecades after the age of 65, but currently only a single vaccination
ith PPSV23 is recommended for adults ≥65 years in the United
tates [1]. Therefore, PPSV23 vaccinated seniors will become vul-
erable to pneumococcal disease over time as immunity wanes and
isease risk increases. The ACIP in the United States does not recom-
end routine revaccinations with PPSV23 and, importantly, receipt
f a ﬁrst dose of the free (unconjugated) polysaccharide vaccine has
een shown to negatively impact the immune responses to subse-
uent doses of PPSV23 [4,5,13–16]. Similar reductions in immune
esponses upon re-administrations of other free polysaccharide
accines, such as Neisseria meningitidis vaccines, are also well doc-
mented [17–19]. The underlying mechanism for this observation
s not fully understood, but may  be related to the loss of memory B
ells upon administration of free polysaccharides [20–22]. By con-
rast, such an effect is not seen with protein conjugate vaccines
22,23].
In the present study we assessed whether immunocompetent
dults ≥70 years of age immunized at least 5 years earlier with
PSV23 have more robust responses to a dose of PCV13 compared
o a (repeat) dose of PPSV23. The study included adults with chronic
on-immunocompromising underlying diseases.
As free polysaccharide antigens are T cell independent and
emory B cells are generally not induced, PPSV23 does not lead toe group/sequence on the logarithmic scale.
t t distribution for the mean difference of the logarithms of the measures.
a recall response. In contrast, PCVs have the potential for eliciting
a recall response to subsequent natural exposure or revaccination,
given the T cell-dependent nature of the responses, thus prolong-
ing the period of protection against vaccine-type pneumococcal
disease.
Therefore, this study also evaluated the responses to PCV13
administered 1 year after the study’s initial PCV13 administration,
compared to the responses to PCV13 administered 1 year after
PPSV23. The 1 year interval was  chosen to provide an assessment
of the potential impact of the initial vaccine on subsequent vaccine
response and not as a test of an interval for revaccination that may
be pursued in clinical practice.
We  found that in adults previously vaccinated with PPSV23,
PCV13 elicited statistically signiﬁcantly greater OPA responses for
the majority of serotypes compared to PPSV23. Although an OPA
titer that correlates with protection has not been deﬁned, titers
were generally higher throughout the full range of OPA responses
as shown by RCDCs, suggesting that in PPSV23-preimmunized older
adults PCV13 will afford the same, and potentially better, protection
than PPSV23 against the PCV13-associated serotypes. Additionally,
the OPA responses to a second administration of PCV13 resulted
in a recovery of the responses to levels similar to those after the
ﬁrst dose, indicating that receipt of a ﬁrst dose of PCV13 does not
negatively inﬂuence the ability to respond to a subsequent dose, in
PPSV23-preimmunized older adults.
In contrast, responses to PCV13 given after PPSV23 were statisti-
cally signiﬁcantly lower for all 13 serotypes compared to the initial
PCV13 dose indicating that PPSV23 diminished the response to
subsequent PCV13. The responses after PCV13/PCV13 were statisti-
cally signiﬁcantly greater for 11 of 12 common serotypes compared
to PPSV23/PCV13. This suggests that, in adults who have already
received PPSV23, there may  be advantages to subsequent admin-
istration of PCV13 rather than revaccination with PPSV23. A sub
analysis of different age groups in this study showed that immune
responses of PCV13 in elderly between 70 and 74 and 75 and 79
years of age were largely similar and slightly lower in subjects 80
years and older. Nonetheless the greater responses after admin-
istration of PCV13 compared to PPSV23 remained apparent across
all three age groupings. While PCV13 contains fewer serotypes
than PPSV23, the PCV13-associated serotypes are responsible for
a substantial worldwide burden of pneumococcal disease in adults
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Table 5
Local reactions and systemic events reported after PCV13 vs. PPSV23 and after PCV13/PCV13 vs. PPSV23/PCV13.
PCV13 vs. PPSV23 PCV13/PCV13 vs. PPSV23/PCV13
PCV13 (%) PPSV23 (%) p-Valuea PCV13/PCV13 (%) PPSV23/PCV13 (%) p-Valuea
Local reactions
Rednessb
Any 10.8 22.2 <0.001 12.7 10.1 0.381
Mild  9.5 13.5 0.129 6.9 8.8 0.447
Moderate 4.7 11.5 0.002 6.9 3.6 0.138
Severe 1.7 4.8 0.028 1.8 0.9 0.542
Swellingb
Any 10.4 23.1 <0.001 12.3 14.1 0.577
Mild  8.9 14.0 0.048 10.3 11.9 0.594
Moderate 4.0 13.6 <0.001 3.5 4.8 0.533
Severe 0.0 4.8 <0.001 0.9 0.5 0.696
Painc
Any 51.7 58.5 0.062 58.2 56.6 0.702
Mild  50.1 54.1 0.284 54.3 53.5 0.872
Moderate 7.5 23.6 <0.001 13.0 13.1 >0.999
Severe 1.3 2.3 0.539 0.4 0.9 0.670
Limitation of arm movementd
Any 10.5 27.6 <0.001 16.2 19.9 0.287
Mild  10.3 25.2 <0.001 15.5 18.9 0.326
Moderate 0.3 2.6 0.020 0.9 0.9 >0.999
Severe 0.7 3.0 0.042 0.9 1.4 0.734
Any  local reactione 56.5 64.1 0.033 62.8 60.8 0.612
Systemic events
Fever
Any (≥38 ◦C) 1.0 2.3 0.253 2.6 1.8 0.581
Mild  (≥38 ◦C but <38.5 ◦C) 1.0 2.0 0.535 0.9 1.8 0.529
Moderate (≥38.5 ◦C but <39 ◦C) 0.0 0.0 >0.999 0.9 0.0 0.217
Severe (≥39 ◦C but ≤40 ◦C) 0.0 0.3 0.509 0.4 0.5 >0.999
Fever  >40 ◦C 0.0 0.0 >0.999 0.4 0.0 0.512
Fatigue 34.0 43.3 0.011 28.6 34.3 0.163
Headache 23.7 26.0 0.510 19.1 22.6 0.348
Chills  7.9 11.2 0.162 7.3 9.9 0.363
Rash  7.3 16.4 <0.001 6.0 7.1 0.718
Vomiting 1.7 1.3 0.808 0.4 3.1 0.032
Decreased appetite 10.4 11.5 0.688 8.9 7.4 0.594
New  generalized muscle pain 36.8 44.7 0.034 34.6 35.0 0.955
Aggravated generalized muscle pain 20.6 27.5 0.039 18.0 21.0 0.407
New  generalized joint pain 12.6 14.9 0.413 10.5 12.0 0.644
Aggravated generalized joint pain 11.6 16.5 0.081 12.6 11.7 0.797
Use  of medication to treat pain 22.0 26.6 0.169 19.0 15.4 0.296
Use  of medication to treat fever 3.0 6.2 0.059 3.9 7.4 0.126
Any  systemic eventf 60.3 68.2 0.020 55.5 58.2 0.524
a Exact 2-sided conﬁdence interval and corresponding p-value (based on Chan & Zhang) for the difference in proportions, [13vPnC]–[23vPS];
[PCV13/PCV13]–[PPSV23/PCV13] expressed as a percentage.
b Redness and swelling were categorized as absent if <2.5 cm,  mild if ≥2.5 cm and ≤5.0 cm,  moderate if >5.0 cm and ≤10.0 cm, and severe if >10.0 cm.
c If pain at the injection site was present, subjects were asked to enter the severity as mild if the symptom was easily tolerated, moderate if there was discomfort sufﬁcient
to  interfere with usual activity, and severe if the pain was  incapacitating.
d If limitation of arm movement was present, subjects were asked to enter the severity as mild, if there was some limitation of arm movement; moderate, if the subject
was  unable to move his or her arm above the head but able to move it above the shoulder; and severe, if the subject was unable to move the arm above the shoulder.
e Any local reaction = any pain, any swelling, any redness, or any limitation of arm movement.
f Any systemic event = any fever ≥38 ◦C, any fatigue, any headache, any chills, any rash, any vomiting, any decreased appetite, any new or aggravated generalized muscle
pain,  and any new or aggravated joint pain.
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Pnd are commonly associated with higher morbidity and mortality
24,25]. Since the most common and reliable current method
f microbiologically diagnosing serotype-speciﬁc pneumococcal
isease relies on blood culture isolation, most of the available
ata on disease-associated serotype distribution formally reﬂects
invasive” disease. However, PCV vaccines have been shown in
linical studies to reduce all-cause pneumonia in immunized
opulations, strongly suggesting that the vaccine serotypes are
ssociated with non-bacteremic disease as well [26–30]. In addi-
ion, only PCV13 contains serotype 6A which, unlike type 6B that is
ontained in both vaccines, has been shown to elicit OPA responses
gainst the cross-reactive serotype 6C which is now recognized
s an important cause of pneumococcal disease [11,24]. Although
PSV23 recipients had some response to serotype 6A, most likelydue to cross reactivity from serotype 6B in the vaccine, serotype
6A responses in PCV13 recipients were approximately 10-fold
higher.
Although there was no restriction to the enrollment of minori-
ties, their participation was  low and may  be noted as a potential
limitation of the study. Also the study was not designed to address
the question of immunity duration.
PCV13 had an acceptable safety and reactogenicity proﬁle in
the study population of PPSV23-preimmunized subjects. The inci-
dence of most types of local reactions was signiﬁcantly higher
after vaccination with PPSV23 than after PCV13 and is likely to be
related to revaccination with PPSV23 containing a higher amount
of polysaccharide antigen. This is consistent with ﬁndings in a prior
dose ranging study [31]. Some systemic events were also more
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requent after vaccination with PPSV23 than after PCV13. Revacci-
ation with PCV13 1 year after PCV13 or PPSV23 was not associated
ith increased reactogenicity.
. Conclusion
In summary, in PPSV23-preimmunized older adults ≥70 years
f age, PCV13 resulted in signiﬁcantly greater anti-pneumococcal
unctional antibody responses for the majority of the PCV13
erotypes compared to PPSV23. Importantly, PCV13 did not neg-
tively inﬂuence the responses to a second dose of PCV13, whereas
PSV23 resulted in lower responses to a subsequent dose of PCV13.
hese ﬁndings indicate that in PPSV23-preimmunized older adults,
CV13 may  be better suited than PPSV23 to re-establish, maintain,
nd generate anti-pneumococcal recall responses. Post marketing
urveillance in multiple countries is ongoing to conﬁrm effective-
ess of PCV13 in PPSV23 pre-immunized elderly adults.
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